TheStreet downgraded shares of Syndax Pharmaceuticals (NASDAQ:SNDX) from a c- rating to a d rating in a research report released on Friday morning.

Other analysts also recently issued research reports about the company. BidaskClub upgraded Syndax Pharmaceuticals from a hold rating to a buy rating in a research note on Saturday, March 24th. B. Riley started coverage on Syndax Pharmaceuticals in a research note on Friday, January 5th. They issued a buy rating and a $40.00 target price on the stock. Zacks Investment Research upgraded Syndax Pharmaceuticals from a hold rating to a buy rating and set a $10.00 target price on the stock in a research note on Wednesday, January 10th. Morgan Stanley lowered their target price on Syndax Pharmaceuticals from $25.00 to $24.00 and set an overweight rating on the stock in a research note on Wednesday, March 14th. Finally, ValuEngine upgraded Syndax Pharmaceuticals from a strong sell rating to a sell rating in a research note on Tuesday, March 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and seven have given a buy rating to the company’s stock. The stock currently has a consensus rating of Buy and an average price target of $23.86.

How to Become a New Pot Stock Millionaire

Shares of SNDX stock opened at $10.76 on Friday. The stock has a market capitalization of $282.05, a PE ratio of -3.71 and a beta of 1.04. Syndax Pharmaceuticals has a fifty-two week low of $7.41 and a fifty-two week high of $15.43.

Syndax Pharmaceuticals (NASDAQ:SNDX) last issued its earnings results on Monday, March 5th. The company reported ($0.80) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.04). Syndax Pharmaceuticals had a negative return on equity of 63.51% and a negative net margin of 2,884.34%. The company had revenue of $1.19 million during the quarter, compared to analysts’ expectations of $0.75 million. The business’s revenue for the quarter was up 290.2% compared to the same quarter last year. sell-side analysts anticipate that Syndax Pharmaceuticals will post -3.52 EPS for the current fiscal year.

In other Syndax Pharmaceuticals news, insider Peter Ordentlich sold 7,500 shares of the stock in a transaction that occurred on Tuesday, April 3rd. The stock was sold at an average price of $15.00, for a total transaction of $112,500.00. The sale was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 24.10% of the company’s stock.

A number of hedge funds have recently modified their holdings of the business. BVF Inc. IL purchased a new position in Syndax Pharmaceuticals during the fourth quarter worth approximately $28,326,000. Millennium Management LLC boosted its position in Syndax Pharmaceuticals by 18.9% during the fourth quarter. Millennium Management LLC now owns 516,500 shares of the company’s stock worth $4,525,000 after purchasing an additional 82,256 shares in the last quarter. Geode Capital Management LLC boosted its position in Syndax Pharmaceuticals by 17.4% during the fourth quarter. Geode Capital Management LLC now owns 153,483 shares of the company’s stock worth $1,344,000 after purchasing an additional 22,803 shares in the last quarter. Crestline Management LP boosted its position in Syndax Pharmaceuticals by 55.3% during the fourth quarter. Crestline Management LP now owns 83,139 shares of the company’s stock worth $728,000 after purchasing an additional 29,607 shares in the last quarter. Finally, State Street Corp boosted its position in Syndax Pharmaceuticals by 32.8% during the second quarter. State Street Corp now owns 81,327 shares of the company’s stock worth $1,137,000 after purchasing an additional 20,106 shares in the last quarter. Institutional investors own 69.55% of the company’s stock.

ILLEGAL ACTIVITY WARNING: “Syndax Pharmaceuticals (SNDX) Lowered to “D” at TheStreet” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this piece of content on another website, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark law. The correct version of this piece of content can be accessed at https://www.dailypolitical.com/2018/04/17/syndax-pharmaceuticals-sndx-lowered-to-d-at-thestreet.html.

About Syndax Pharmaceuticals

Syndax Pharmaceuticals, Inc (Syndax) is a clinical stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The Company’s product candidate, entinostat, which was granted Breakthrough Therapy designation by the FDA following positive results from its Phase IIb clinical trial, ENCORE 301, is being evaluated in a Phase III clinical trial for advanced hormone receptor positive breast cancer.

Analyst Recommendations for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.